SG11202104686QA - Ret inhibitors, pharmaceutical compositions and uses thereof - Google Patents
Ret inhibitors, pharmaceutical compositions and uses thereofInfo
- Publication number
- SG11202104686QA SG11202104686QA SG11202104686QA SG11202104686QA SG11202104686QA SG 11202104686Q A SG11202104686Q A SG 11202104686QA SG 11202104686Q A SG11202104686Q A SG 11202104686QA SG 11202104686Q A SG11202104686Q A SG 11202104686QA SG 11202104686Q A SG11202104686Q A SG 11202104686QA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- ret inhibitors
- ret
- inhibitors
- pharmaceutical
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811496406 | 2018-12-07 | ||
| CN201910245269 | 2019-03-28 | ||
| CN201910248485 | 2019-03-29 | ||
| PCT/CN2019/123698 WO2020114494A1 (en) | 2018-12-07 | 2019-12-06 | Ret inhibitors, pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104686QA true SG11202104686QA (en) | 2021-06-29 |
Family
ID=70973997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104686QA SG11202104686QA (en) | 2018-12-07 | 2019-12-06 | Ret inhibitors, pharmaceutical compositions and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12312348B2 (en) |
| EP (1) | EP3891148A4 (en) |
| JP (1) | JP7457708B2 (en) |
| KR (1) | KR20210100155A (en) |
| CN (1) | CN111285874B (en) |
| AU (1) | AU2019394519B2 (en) |
| CA (1) | CA3117850A1 (en) |
| SG (1) | SG11202104686QA (en) |
| WO (1) | WO2020114494A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117854A1 (en) * | 2018-12-07 | 2020-06-11 | Sunshine Lake Pharma Co., Ltd. | Ret inhibitors, pharmaceutical compositions and uses thereof |
| WO2021043209A1 (en) * | 2019-09-04 | 2021-03-11 | 广东东阳光药业有限公司 | Ret inhibitor, pharmaceutical composition and use thereof |
| CN112574235B (en) * | 2019-09-29 | 2024-01-16 | 广东东阳光药业股份有限公司 | A RET inhibitor, its pharmaceutical composition and its use |
| WO2021057970A1 (en) * | 2019-09-29 | 2021-04-01 | 广东东阳光药业有限公司 | Ret inhibitor, pharmaceutical composition thereof and use thereof |
| AU2020410900B2 (en) * | 2019-12-27 | 2024-06-13 | Tyk Medicines, Inc. | Compound used as RET kinase inhibitor and application thereof |
| CN113880865A (en) * | 2020-07-01 | 2022-01-04 | 上海艾力斯医药科技股份有限公司 | Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof |
| TWI818424B (en) * | 2021-02-08 | 2023-10-11 | 大陸商北京志健金瑞生物醫藥科技有限公司 | Nitrogen-containing polycyclic fused ring compound, pharmaceutical composition, preparation method and use thereof |
| CN113121537B (en) * | 2021-04-13 | 2022-11-08 | 南通药明康德医药科技有限公司 | Synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate |
| TW202504611A (en) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086042A1 (en) * | 2011-04-28 | 2013-11-13 | Galapagos Nv | USEFUL COMPOUND FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITION |
| CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
| EP3322706B1 (en) * | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| CA3033752C (en) | 2016-08-15 | 2022-05-31 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
| JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TWI704148B (en) * | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| CN110267960B (en) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors |
| JP2022503932A (en) | 2018-09-27 | 2022-01-12 | フォチョン・ファーマシューティカルズ・リミテッド | Substituted imidazole [1,2-A] pyridine and [1,2,4] triazolo [1,5-A] pyridine compounds as RET kinase inhibitors |
| CA3117854A1 (en) | 2018-12-07 | 2020-06-11 | Sunshine Lake Pharma Co., Ltd. | Ret inhibitors, pharmaceutical compositions and uses thereof |
| WO2021043209A1 (en) * | 2019-09-04 | 2021-03-11 | 广东东阳光药业有限公司 | Ret inhibitor, pharmaceutical composition and use thereof |
| CN112574235B (en) * | 2019-09-29 | 2024-01-16 | 广东东阳光药业股份有限公司 | A RET inhibitor, its pharmaceutical composition and its use |
| WO2021057970A1 (en) * | 2019-09-29 | 2021-04-01 | 广东东阳光药业有限公司 | Ret inhibitor, pharmaceutical composition thereof and use thereof |
-
2019
- 2019-12-06 CN CN201911244557.9A patent/CN111285874B/en active Active
- 2019-12-06 KR KR1020217021077A patent/KR20210100155A/en active Pending
- 2019-12-06 WO PCT/CN2019/123698 patent/WO2020114494A1/en not_active Ceased
- 2019-12-06 JP JP2021532056A patent/JP7457708B2/en active Active
- 2019-12-06 AU AU2019394519A patent/AU2019394519B2/en active Active
- 2019-12-06 SG SG11202104686QA patent/SG11202104686QA/en unknown
- 2019-12-06 US US17/289,192 patent/US12312348B2/en active Active
- 2019-12-06 CA CA3117850A patent/CA3117850A1/en active Pending
- 2019-12-06 EP EP19891877.3A patent/EP3891148A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020114494A1 (en) | 2020-06-11 |
| EP3891148A1 (en) | 2021-10-13 |
| CA3117850A1 (en) | 2020-06-11 |
| AU2019394519B2 (en) | 2025-02-13 |
| CN111285874B (en) | 2024-08-09 |
| CN111285874A (en) | 2020-06-16 |
| JP2022510689A (en) | 2022-01-27 |
| US20220119382A1 (en) | 2022-04-21 |
| US12312348B2 (en) | 2025-05-27 |
| JP7457708B2 (en) | 2024-03-28 |
| EP3891148A4 (en) | 2022-09-07 |
| AU2019394519A1 (en) | 2021-05-20 |
| KR20210100155A (en) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202104687SA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| SG11202104686QA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| SMT202100012T1 (en) | Pharmaceutical compositions comprising meloxicam and rizatriptan | |
| IL271657A (en) | Pharmaceutical compositions | |
| IL269061A (en) | Pharmaceutical composition comprising selexipag | |
| IL271759B1 (en) | Pharmaceutical compositions comprising entrectinib | |
| EP3381925A4 (en) | Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof | |
| IL248785B (en) | N-[1,5-dimethyl-3-oxo-(2,3-dihydro-1h-pyrazol-4-yl)]-4-methyl-isoxazole-3-carboxamide derivatives and pharmaceutical compositions comprising said derivatives | |
| GB201807053D0 (en) | Pharmaceutical composition | |
| IL281357A (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| GB201705303D0 (en) | Pharmaceutical compositions | |
| GB201804548D0 (en) | Pharmaceutical compositions | |
| GB201705304D0 (en) | Pharmaceutical compositions | |
| GB201705305D0 (en) | Pharmaceutical compositions | |
| IL279877A (en) | Ivosidenib forms and pharmaceutical compositions | |
| ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
| GB201808571D0 (en) | Pharmaceutical compositions | |
| PH12017502148A1 (en) | Pharmaceutical compositions and use thereof | |
| GB201705306D0 (en) | Pharmaceutical compositions | |
| ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof | |
| GB201808567D0 (en) | Pharmaceutical compositions | |
| ZA202000014B (en) | Pharmaceutical compositions | |
| SG11202103374TA (en) | Pharmaceutical composition | |
| ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof |